Adaptive Biotechnologies Corporation is rated Hold as MRD segment momentum offset by competitive & valuation concerns. Read ...

With a new edition of a long-running awareness campaign, Genentech is drawing attention to the talents and passions that are helping people with multiple sclerosis (MS) thrive. | With a new edition of ...

A flurry of deal-making hasn’t let up as 2025 comes to a close, with Roche subsidiary Genentech getting in on the action and ...

Genentech, a subsidiary of the Roche Group, has received the US FDA accelerated approval for Lunsumio VELO SC formulation to ...

Caris Life Sciences said on Tuesday it has signed a multi-year collaboration with Genentech, part of Swiss drugmaker Roche, to discover new drug targets for hard-to-treat cancers. The agreement ...

Genentech will leverage Medra's Physical AI, Scientific AI and robotics into its lab systems to accelerate drug discovery.

The US FDA has approved a subcutaneous version of Roche (RHHBY)-owned Genentech's follicular lymphoma treatment, Lunsumio ...

Genentech recently announced a series of marketing leadership hires to start off the new year. The biotech company hired Erica Taylor, PhD, as the company’s first chief marketing officer and tabbed ...

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for ...

Missing a trial goal in Alzheimer’s disease is a pretty common occurrence—see crenezumab, for the latest. But Genentech’s latest reported miss was something different. The Roche unit wanted to build a ...

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute –– Availability of Lunsumio VELO allows ...